ACE 031 Vials
|Molar Mass||1311.45 g/mol|
|IUPAC Name||UNII-U8DGS69FVC U8DGS69FVC 1621169-52-5 CHEMBL3410227 Myostatin inhibitory peptide 7 BDBM50071379 ACE-031 Myostatin inhibitory peptide 7 Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2|
ACE 031 Vials represent an advanced research product tailored exclusively for scientific inquiry. It is imperative to emphasize that these vials are intended solely for research purposes, and any mention of human consumption is strictly prohibited.
Each ACE 031 Vial contains a precisely measured quantity of ACE 031, a research peptide known for its potential applications in the study of musculoskeletal and metabolic processes. The product adheres to stringent quality standards, ensuring accuracy and reliability in research settings.
ACE 031 Vials find application in diverse research areas, particularly focusing on musculoskeletal studies and energy metabolism. Researchers can utilize this product to investigate the physiological effects of ACE 031 in controlled experimental conditions.
ACE 031 and Energy Metabolism Research
Research suggests a potential link between ACE 031 and energy metabolism. Studies indicate that ACE 031 may play a role in influencing metabolic processes, contributing to enhanced energy utilization.
ACE 031 and Muscle Repair
Preliminary findings propose that ACE 031 may have implications for muscle repair. Research in animal models suggests that ACE 031 could potentially enhance the regenerative capacity of muscles following injury or stress.
ACE 031 and Bone Density:
Exploratory studies indicate potential implications of ACE 031 in bone density research. Investigations suggest that ACE 031 may contribute to increased bone mineral density, offering potential benefits for skeletal health.
ACE 031 Vials serve as a valuable tool for researchers engaged in musculoskeletal and metabolic studies. Rigorous adherence to research protocols ensures the credibility of findings in various experimental contexts..
- Relizani K, Mouisel E, Giannesini B, Hourdé C, Patel K, Morales Gonzalez S, Jülich K, Vignaud A, Piétri-Rouxel F, Fortin D, Garcia L, Blot S, Ritvos O, Bendahan D, Ferry A, Ventura-Clapier R, Schuelke M, Amthor H. Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. Mol Ther. 2014 Aug;22(8):1423-1433. doi: 10.1038/mt.2014.90. Epub 2014 May 27. PMID: 24861054; PMCID: PMC4435590. [Read More]
- Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, Wilson DM, Sherman ML, Escolar D, Attie KM. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017 Apr;55(4):458-464. doi: 10.1002/mus.25268. Epub 2016 Dec 23. PMID: 27462804. [Read More]
- Puolakkainen T, Ma H, Kainulainen H, Pasternack A, Rantalainen T, Ritvos O, Heikinheimo K, Hulmi JJ, Kiviranta R. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. BMC Musculoskelet Disord. 2017 Jan 19;18(1):20. doi: 10.1186/s12891-016-1366-3. PMID: 28103859; PMCID: PMC5244551. [Read More]